Phenoxypropazine

Phenoxypropazine
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (1-methyl-2-phenoxy-ethyl)hydrazine;
CAS Number	3818-37-9;
PubChem CID	71467;
ChemSpider	64548;
UNII	8E92V52324;
ChEMBL	ChEMBL1909286;
CompTox Dashboard (EPA)	DTXSID1048837 ;
Chemical and physical data
Formula	C9H14N2O
Molar mass	166.22 g/mol g·mol−1

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.^[1]^[2]^[3]^[4]^[5]

References

^ LEAHY MR, ROSE JT, PLOWMAN R (April 1963). "A preliminary study of phenoxypropazine in the treatment of depression". The American Journal of Psychiatry. 119: 986–7. PMID 13928824.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ IMLAH NW (May 1963). "Preliminary report on phenoxypropazine". The American Journal of Psychiatry. 119: 1091–2. PMID 13956423.
^ ROSE JT, LEAHY MR, PLOWMAN R (October 1963). "A comparison of phenoxypropazine and amitriptyline in depression". The American Journal of Psychiatry. 120: 393–5. PMID 14069469.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ ROSE JT (March 1964). "Phenoxypropazine and chlordiazepoxide in depression". The American Journal of Psychiatry. 120: 899–900. PMID 14129290.
^ MCWHINNEY IR, MORRELL DC (January 1965). "Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice". The Journal of the College of General Practitioners. 9: 95–9. PMC 1878242. PMID 14254271.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.